Skip to main content
    L

    Legend Biotech Corp (LEGN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $16.11
    +0.12 (+0.75%)

    Market Cap: $3.10B

    Last updated: Nov 17, 2026 at 4:39 PM ET

    Legend Biotech Corp (LEGN) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Legend Biotech (LEGN) has a market cap of $3.10B. Revenue grew 49.45% over the last 12 months from the 12 months before. Its share count is up 4.96% from a year earlier.

    Total Valuation

    Market Cap$3.10B
    Latest price (Nov 17, 2026)$16.11

    Key Dates

    The next earnings report is expected on Mar 8, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 8, 2027 (expected)
    Last Earnings DateNov 10, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count held steady in the quarter ended Sep 30, 2026 and grew 2.99% a year over 2 years.

    Shares Outstanding193.80M
    Shares Change (YoY)+4.96%
    Shares Change (QoQ)0.00%
    Share Count Growth (2Y CAGR)+2.99%

    Valuation Ratios

    Sales and book value multiples are 2.3x and 2.5x.

    P/E Ratio268.5x
    P/S Ratio2.3x
    Forward P/S2.2x
    P/B Ratio2.5x
    P/TBV Ratio2.6x

    Valuation history and multiples

    Price Statistics

    The stock is down 46.81% over 52 weeks and trades 16.83% below its 50-day average.

    Beta (1Y)0.67
    52-Week Change-46.81%
    1-Month Change-13.62%
    3-Month Change-28.72%
    6-Month Change-40.20%
    5-Year Change-58.80%
    Total Return (1Y)-46.81%
    Total Return (3Y CAGR)-37.04%
    Total Return (5Y CAGR)-21.75%
    Return vs SPY (1Y)-56.80%
    Max Drawdown (1Y)-55.93%
    Max Drawdown (3Y)-77.15%
    Sharpe Ratio (1Y)-0.80
    Correlation with SPY (1Y)0.12
    50-Day Average$19.37
    200-Day Average$22.18
    52-Week Range$15.97 to $37.50
    RSI (14 Days)33.8
    Average Volume (20 Days)2.61M

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 3.95x current liabilities.

    Current Ratio3.95x
    Quick Ratio3.82x
    Interest Coverage3.27x

    Returns and Efficiency

    Return on equity is -0.02% over the last 12 months, against a 5-year average of -40.14%.

    Return on Equity (ROE)-0.02%
    Return on Assets (ROA)-0.01%
    Return on Capital Employed (ROCE)3.54%
    ROE (5Y Average)-40.14%
    ROA (5Y Average)-25.07%
    ROIC (5Y Average)-29.36%
    Asset Turnover0.80x
    Inventory Turnover14.38x
    Receivables Turnover6.52x
    Cash Conversion Cycle35 days

    Scores

    LEGN has an Altman Z-Score of 4.49, in the safe zone above 2.99, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.

    Altman Z-Score4.49
    Altman Z ZoneSafe
    Piotroski F-Score2 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue was $1.36B over the last 12 months.

    Revenue$1.36B
    Revenue Growth (YoY)+49.45%
    Gross Profit$774.12M
    Operating Income$34.10M
    Pretax Income$32.20M
    Net Income-$215.00K
    EBITDA$99.55M
    EBIT$49.28M
    Reported EPS (TTM)$0.06

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 75.60% of the $1.68B in total assets.

    Cash and Equivalents$460.70M
    Working Capital$855.20M
    Shareholder Equity$1.27B
    Tangible Book Value$1.20B
    Total Assets$1.68B
    Total Liabilities$408.70M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $73.11M of capital spending, operating cash flow left -$320.91M of free cash flow.

    Operating Cash Flow-$247.80M
    Capital Expenditures$73.11M
    Free Cash Flow-$320.91M
    FCF Per Share-$1.65
    Depreciation and Amortization$50.27M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is 2.51%.

    Gross Margin56.98%
    Operating Margin2.51%
    Pretax Margin2.37%
    Net Margin-0.02%
    EBITDA Margin7.33%
    EBIT Margin3.63%
    FCF Margin-23.62%
    Gross Margin (5Y Average)63.30%

    Growth

    Revenue grew 106.41% a year over 3 years.

    Revenue Growth (3Y CAGR)+106.41%
    Revenue Growth (5Y CAGR)+68.83%

    Revenue and profit by year

    Dividends and Yields

    LEGN does not pay a dividend. Its free cash flow yield is -10.28%.

    Earnings Yield0.37%
    FCF Yield-10.28%
    Shareholder Yield0.00%

    Peer Position

    Against 6 similar companies, LEGN has the lowest P/S.

    P/S Ratio2.3x vs 11.9x median
    Revenue Growth (Trailing 4 Quarters, YoY)+49.45% vs -78.40% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 22.22% a year over the next 5 fiscal years.

    Revenue Growth Forecast (5Y CAGR)+22.22%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About LEGN

    What is LEGN's market cap?

    Legend Biotech has a market cap of $3.10B.

    What is LEGN's P/E ratio?

    Legend Biotech has a trailing P/E ratio of 268.5x.

    How many shares of LEGN are outstanding?

    Legend Biotech has 193.80M shares outstanding. The count is up 4.96% from a year earlier.

    Does LEGN pay a dividend?

    No. Legend Biotech does not pay a dividend.